• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

    0.9911 +0.0744 (+8.12%)
    Streaming Delayed Price Updated: 11:10 AM EDT, Aug 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Tempest Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
    Webcasted conference call on Thursday, June 20, 2024 at 8:30 a.m. ET 
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    “Market Mavericks: Stocks Creating Ripples of Success” CLNV, TPST, HNRC, INPX
    Via AB Newswire
    News headline image
    Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    Tempest to Participate in Upcoming Investor Conferences
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q1 2024 ↗
    TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    News headline image
    Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
    Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. 
    Via Benzinga
    News headline image
    Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 ↗
    TPST stock results show that Tempest Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    News headline image
    Tempest Reports Year End 2023 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    News headline image
    Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tempest Therapeutics Announces Groundbreaking Advances in Liver Cancer Treatment, Showcasing Exceptional Efficacy and Safety Data at ASCO Annual Meeting 2024
    Via AB Newswire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
     
    Via Benzinga
    News headline image
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
    From Tempest Therapeutics
    Via GlobeNewswire
    Intelligent Bio (NASDAQ: INBS) Surges Massively Among Stocks Making BUZZ:TPST, HNST, LTRN, VTAK
    Via AB Newswire
    News headline image
    Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
    Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Crude Oil Rises Over 1%; Tapestry Posts Upbeat Earnings ↗
    U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The Dow traded up 0.01% to 34,114.64 while the NASDAQ rose 0.35% to 13,697.53.... 
    Via Benzinga
    Topics Stocks
    News headline image
    Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    News headline image
    Biggest Short Squeeze Stocks Of The Week: Two Biotech Stocks Move Up To Top The List ↗
    Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.